AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9112219 — intervention group
Group type: EXPERIMENTAL
Intervention: CFU‐GM and CD34+ cells/kg
Number of subjects: 45
Study 9112219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior chemotherapy cycles
Number of subjects: 45
Study 9112219 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cell enumeration
Number of subjects: 45
Study 9112219 — intervention group
Group type: EXPERIMENTAL
Intervention: CFU‐GM clonogenic assays
Number of subjects: 45
Study 7901248 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diphenylcyclopropenone (DPCP)
Number of subjects: 15
Study 7901248 — intervention group
Group type: COMPARATOR
Intervention: Topical 5% minoxidil
Number of subjects: 15
Study 3306128 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted therapy
Number of subjects: 611
Study 3306128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose Methotrexate
Number of subjects: 611
Study 31820537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (97/103 mg b.i.d.)
Number of subjects: 286
Study 31820537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 286
Study 29099231 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (8 × 2 minutes at 90% peak power output)
Number of subjects: 48
Study 29099231 — intervention group
Group type: EXPERIMENTAL
Intervention: supra-HIIT (8 × 20 seconds at 170% peak power output)
Number of subjects: 48
Study 29099231 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 48
Study 28553078 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin extended release (XR)
Number of subjects: 253
Study 28553078 — intervention group
Group type: COMPARATOR
Intervention: Metformin immediate release (IR)
Number of subjects: 253
Study 26169960 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict treatment of CVD risk factors and lifestyle recommendations as per a prespecified protocol.
Number of subjects: 111
Study 26169960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid- and/or blood pressure-lowering drugs prescribed to 69% of patients.
Number of subjects: 111
Study 26169960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice given to 42% of patients.
Number of subjects: 111
Study 26169960 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise advised to 67% of patients.
Number of subjects: 111
Study 26169960 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to lifestyle recommendations across CVD risk groups.
Number of subjects: 111
Study 23046107 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin (5 mg medroxyprogesterone acetate/day for 30 days)
Number of subjects: 216
Study 23046107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one pill/day for 30 days)
Number of subjects: 216
Study 20675975 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-sNT (morphine sulfate and naltrexone hydrochloride extended release capsules)
Number of subjects: 547
Study 20675975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 18212335 — intervention group
Group type: EXPERIMENTAL
Intervention: High elaboration (need for cognition, personal relevance)
Number of subjects: 0
Study 18212335 — intervention group
Group type: EXPERIMENTAL
Intervention: Low elaboration
Number of subjects: 0
Study 20393176 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa (20 mg/kg biweekly for 78 weeks)
Number of subjects: 90
Study 20393176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16392706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice diet (protein, 6.3 g; fat, 0.9 g; CHO, 79.3 g; energy, 368 kcal)
Number of subjects: 10
Study 16392706 — intervention group
Group type: COMPARATOR
Intervention: Bread diet (protein, 15.7 g; fat, 5.8 g; CHO, 79.2 g; energy, 450 kcal)
Number of subjects: 10
Study 11870127 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HSP 60 IgA Ab in seminal fluid (total positive 6.9%)
Number of subjects: 202
Study 11870127 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal IgA Ab to human HSP 60
Number of subjects: 202
Study 9758298 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-I atypical lymphocytes (AL) detected in cerebrospinal fluid (CSF)
Number of subjects: 148
Study 9758298 — intervention group
Group type: COMPARATOR
Intervention: Type-I atypical lymphocytes (AL)
Number of subjects: 148
Study 9758298 — intervention group
Group type: COMPARATOR
Intervention: Type-II atypical lymphocytes (AL)
Number of subjects: 148
Study 9758298 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of type-I atypical lymphocytes (AL) in CSF
Number of subjects: 148
Study 9758298 — intervention group
Group type: COMPARATOR
Intervention: Presence of type-II atypical lymphocytes (AL)
Number of subjects: 148
Study 9316692 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100)
Number of subjects: 9
Study 9316692 — intervention group
Group type: COMPARATOR
Intervention: Controlled release levodopa/carbidopa 50/200
Number of subjects: 9
Study 2853961 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg orally
Number of subjects: 12
Study 2853961 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 5 mg orally 3 h before
Number of subjects: 12
Study 2853961 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 29883070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (SITA group; n = 20)
Number of subjects: 40
Study 29883070 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (CONT group; n = 20)
Number of subjects: 40
Study 27807604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-4.5 mg/day)
Number of subjects: 93
Study 26923796 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PDA)
Number of subjects: 0
Study 26923796 — intervention group
Group type: COMPARATOR
Intervention: Informational resource sheet
Number of subjects: 0
Study 24487558 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl-cyanoacrylate
Number of subjects: 609
Study 24487558 — intervention group
Group type: COMPARATOR
Intervention: metal staples
Number of subjects: 609
Study 22985001 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (targeting children, parents, and school staff)
Number of subjects: 392
Study 22985001 — intervention group
Group type: EXPERIMENTAL
Intervention: Student intervention (targeting only children)
Number of subjects: 392
Study 22985001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 392
Study 18083635 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-Pressure group (50mmHg)
Number of subjects: 21
Study 18083635 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-Pressure group (150mmHg)
Number of subjects: 21
Study 18083635 — intervention group
Group type: COMPARATOR
Intervention: 0-Pressure group (no pressure)
Number of subjects: 21
Study 18083635 — intervention group
Group type: COMPARATOR
Intervention: 250-Pressure group (250mmHg)
Number of subjects: 21
Study 18083635 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups with vascular occlusion
Number of subjects: 21
Study 18083635 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 21
Study 17965785 — intervention group
Group type: EXPERIMENTAL
Intervention: Isothermic carbon dioxide (37 degrees C)
Number of subjects: 62
Study 17965785 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic carbon dioxide (21 degrees C)
Number of subjects: 62
Study 15499763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate lotion
Number of subjects: 222
Study 15499763 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate cream
Number of subjects: 222
Study 15499763 — intervention group
Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 222
Study 11549974 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10‐mg wafer
Number of subjects: 458
Study 11549974 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 5‐mg wafer
Number of subjects: 458
Study 11549974 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 458
Study 9715738 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-s sprint
Number of subjects: 8
Study 9715738 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-s sprint
Number of subjects: 8
Study 9715738 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-s sprint after 10-s sprint
Number of subjects: 8
Study 9715738 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-s sprint after 20-s sprint
Number of subjects: 8
Study 8150244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 2906290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral yohimbine (0.2 mg kg-1)
Number of subjects: 0
Study 2906290 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (0.5 mg kg-1; 60 min before yohimbine)
Number of subjects: 0
Study 2906290 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 0
Study 2906290 — intervention group
Group type: COMPARATOR
Intervention: Post-meal condition
Number of subjects: 0
Study 29848211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 80% of VO2max for 50 minutes
Number of subjects: 33
Study 29848211 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhausting running
Number of subjects: 33
Study 29848211 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhausting cycling
Number of subjects: 33
Study 29848211 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise (cycling and running) until exhaustion
Number of subjects: 33
Study 29848211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 33
Study 26482233 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 2293
Study 26482233 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRIA score
Number of subjects: 2293
Study 26482233 — intervention group
Group type: EXPERIMENTAL
Intervention: ORBIT score
Number of subjects: 2293
Study 26482233 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRIA and ORBIT scores
Number of subjects: 2293
Study 25271544 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 11997
Study 25271544 — intervention group
Group type: COMPARATOR
Intervention: Selective oropharyngeal decontamination (SOD)
Number of subjects: 11997
Study 22925198 — intervention group
Group type: COMPARATOR
Intervention: mADM
Number of subjects: 0
Study 22925198 — intervention group
Group type: EXPERIMENTAL
Intervention: mADM plus MBCT
Number of subjects: 0
Study 22925198 — intervention group
Group type: COMPARATOR
Intervention: MBCT
Number of subjects: 0
Study 19930765 — intervention group
Group type: EXPERIMENTAL
Intervention: Berry purée with 35 g sucrose
Number of subjects: 12
Study 19930765 — intervention group
Group type: COMPARATOR
Intervention: Control sucrose load
Number of subjects: 12
Study 18842125 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (progressive functional strength training program)
Number of subjects: 51
Study 18842125 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study 15933563 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (90/6.4 mg/kg/d in 2 divided doses for 10 days)
Number of subjects: 730
Study 15933563 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (10 mg/kg for 1 day followed by 5 mg/kg/d for 4 days)
Number of subjects: 730
Study 15933563 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 730
Study 15933563 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 730
Study 12124714 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond laser scalpel
Number of subjects: 18
Study 12124714 — intervention group
Group type: COMPARATOR
Intervention: Steel scalpel with electrocoagulation
Number of subjects: 18
Study 10747531 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (daily collection of blood pressure, pulse, and weight data; weekly video conference with nurse)
Number of subjects: 20
Study 10747531 — intervention group
Group type: COMPARATOR
Intervention: Control (blood pressure, weight, and pulse measured at six weekly intervals)
Number of subjects: 20
Study 8751028 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (open-label)
Number of subjects: 16
Study 8751028 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of flunarizine
Number of subjects: 16
Study 8751028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 2096499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg body weight single dose
Number of subjects: 113
Study 2096499 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 25 mg/kg body weight over 3 days
Number of subjects: 113
Study 866041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor immersion of the hand
Number of subjects: 80
Study 866041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor immersion of the finger
Number of subjects: 80
Study 866041 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 80
Study 31943069 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC) performed after 48 hours since stroke diagnosis
Number of subjects: 66
Study 31943069 — intervention group
Group type: COMPARATOR
Intervention: Decompressive craniectomy (DC) performed within 48 hours since stroke diagnosis
Number of subjects: 66
Study 30337172 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated monovalent influenza A/H1N1 vaccine (IIV), two doses administered three weeks apart
Number of subjects: 48
Study 25920528 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 692
Study 25048074 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric load at 138% of concentric load
Number of subjects: 40
Study 25048074 — intervention group
Group type: COMPARATOR
Intervention: Eccentric load at 0%, 33%, 66%, and 100% of concentric load
Number of subjects: 40
Study 25048074 — intervention group
Group type: COMPARATOR
Intervention: Eccentric load at 0%
Number of subjects: 40
Study 22147839 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic ablation of ganglionated plexi (GP) in the right atrium
Number of subjects: 34
Study 22147839 — intervention group
Group type: COMPARATOR
Intervention: Selective ablation procedure targeting vagal reflex
Number of subjects: 34
Study 20697291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Lactobacillus plantarum LP01 and Bifidobacterium breve BR03 (2.5 x 10 colony-forming units/d of each strain)
Number of subjects: 300
Study 20697291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subspecies lactis BS01 (5 x 10 colony-forming units/d)
Number of subjects: 300
Study 20697291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 18188760 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message intervention
Number of subjects: 249
Study 18188760 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message intervention
Number of subjects: 249
Study 18188760 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived risk of quitting
Number of subjects: 249
Study 16193197 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts (20 grams per day for 8 weeks)
Number of subjects: 52
Study 16193197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no walnuts)
Number of subjects: 52
Study 12642354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 12642354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhVEGF (17 ng x kg(‐1) x min(‐1))
Number of subjects: 178
Study 12642354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhVEGF (50 ng x kg(‐1) x min(‐1))
Number of subjects: 178
Study 10590183 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin) administered with tissue plasminogen activator
Number of subjects: 0
Study 10590183 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide (Integrilin)
Number of subjects: 0
Study 10590183 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-treated patients
Number of subjects: 0
Study 9081272 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S) 200 micrograms via inhaler 15 minutes prior to exercise
Number of subjects: 17
Study 9081272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 17
Study 8168235 — intervention group
Group type: EXPERIMENTAL
Intervention: pyquiton at a single dose of 10.5 mg/kg
Number of subjects: 200
Study 8168235 — intervention group
Group type: EXPERIMENTAL
Intervention: pyquiton at a single dose of 2.5 mg/kg
Number of subjects: 200
Study 8168235 — intervention group
Group type: EXPERIMENTAL
Intervention: pyquiton at a single dose (not specified)
Number of subjects: 200
Study 8168235 — intervention group
Group type: EXPERIMENTAL
Intervention: pyquiton (not specified dosage)
Number of subjects: 200
Study 3021082 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of naloxone hydrochloride and yohimbine hydrochloride
Number of subjects: 0
Study 3021082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3021082 — intervention group
Group type: COMPARATOR
Intervention: Naloxone hydrochloride alone
Number of subjects: 0
Study 3021082 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine hydrochloride alone
Number of subjects: 0
Study 28557869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathel (S)
Number of subjects: 62
Study 28557869 — intervention group
Group type: COMPARATOR
Intervention: Mepilex Ag (M)
Number of subjects: 62
Study 28557869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dressings
Number of subjects: 62
Study 27637517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation on Prescription (TCP)
Number of subjects: 928
Study 27637517 — intervention group
Group type: COMPARATOR
Intervention: Current practice for tobacco cessation
Number of subjects: 928
Study 27637517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 928
Study 24799299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 14
Study 24799299 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 14
Study 22270205 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 mouse units (m.U) of Botox
Number of subjects: 12
Study 22270205 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 mouse units (m.U) of Prosigne
Number of subjects: 12
Study 22270205 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 mouse units (m.U) of Xeomin
Number of subjects: 12
Study 22270205 — intervention group
Group type: EXPERIMENTAL
Intervention: 51 Speywood units (s.U) of Dysport
Number of subjects: 12
Study 22270205 — intervention group
Group type: COMPARATOR
Intervention: All BTXA preparations combined
Number of subjects: 12
Study 20046175 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose 400 mg itraconazole
Number of subjects: 60
Study 20046175 — intervention group
Group type: COMPARATOR
Intervention: 7 day 200 mg daily itraconazole
Number of subjects: 60
Study 18520221 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS) technique without supplementary ligation (NT group)
Number of subjects: 65
Study 18520221 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand-tied ligation technique (CT group)
Number of subjects: 65
Study 15860465 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) for 12 weeks
Number of subjects: 31
Study 15860465 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) for 12 weeks
Number of subjects: 31
Study 15860465 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Strength Training (COMT) for 12 weeks
Number of subjects: 31
Study 15860465 — intervention group
Group type: COMPARATOR
Intervention: No Training (NT)
Number of subjects: 31
Study 15860465 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 31
Study 15860465 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 31
Study 15860465 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Strength Training (COMT)
Number of subjects: 31
Study 11396535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days
Number of subjects: 102
Study 11396535 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days followed by 3 weeks of RBC 400 mg b.d. alone
Number of subjects: 102
Study 9935258 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg alatrofloxacin daily followed by 200 mg oral trovafloxacin daily
Number of subjects: 308
Study 9935258 — intervention group
Group type: COMPARATOR
Intervention: 1 g imipenem/cilastatin intravenously thrice daily followed by 500 mg oral amoxicillin/clavulanic acid thrice daily
Number of subjects: 308
Study 8058076 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of budesonide per day
Number of subjects: 74
Study 8058076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 8058076 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 micrograms of budesonide per day (crossover group)
Number of subjects: 74
Study 11039067 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 gel with 98% available Sn2+ ion, used twice daily for nine months
Number of subjects: 81
Study 11039067 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 gel with less than 2% available Sn2+ ion, used once a day for six months, then twice a day for three months
Number of subjects: 81
Study 11039067 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing alone (control group)
Number of subjects: 81
Study 8130476 — intervention group
Group type: EXPERIMENTAL
Intervention: ComputerLink (electronic network designed to support home care)
Number of subjects: 0
Study 8130476 — intervention group
Group type: EXPERIMENTAL
Intervention: ComputerLink
Number of subjects: 0
Study 347857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0